JBIO
Jade BiosciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About JBIO
Jade Biosciences, Inc.
A biotechnology company dedicated to developing transformative therapies for autoimmune diseases
221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts 02453
--
Jade Biosciences, Inc., is a Nevada company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets cytokine anti-A Proliferation-induced Ligand (APRIL) in immunoglobulin A (IGA) nephropathy, is conducting investigational new drug application enabling studies, and is expected to initiate the first human trial in the second half of 2025. Jade's pipeline also includes two undisclosed antibody discovery projects, JADE-002 and JADE-003, which are currently in preclinical development.
Company Financials
EPS
JBIO has released its 2025 Q3 earnings. EPS was reported at -0.48, versus the expected -0.67, beating expectations. The chart below visualizes how JBIO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
